Loading market dashboard
Establishment Labs Holdings Inc.
ESTAHealthcareNASDAQCR
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Establishment Labs develops advanced silicone implants and medical devices for global plastic surgery markets.
WEST JORDAN, Utah, May 18, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Raj Denhoy to the role of Chief Financial Officer (CFO) effective today. “Route 92 Medical has built a strong position in neurovascular intervention,” said Raj Denhoy, CFO at Route 92 Medical.
This global medtech firm specializing in advanced implant solutions reported a notable insider sale amid a year of strong share performance.
Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.7 per share a year ago.
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2026. First Quarter Highlights and Outlook (Unaudited) Revenue of $59.9 million, up 44.7% from Q1 2025, with guidance raised to $266.5 million to $268.5 million $19.6 million of Motiva sales in the United State.
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into a $300 million senior secured term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The amended and restated facility refinances the company's existing debt and allows access to additional capital to support ongoi.
Award underscores GameSquare's track record of innovation building next-generation esports platforms FRISCO, TX / ACCESS Newswire / April 30, 2026 / GameSquare Holdings, Inc. (NASDAQ:GAME) ("GameSquare" or the "Company") today announced it has been named the winner of the 2026 ESTA Industry Award in the Esports Innovation category, presented by the Esports Trade Association (ESTA). The award recognizes GameSquare's continued innovation in advancing the esports and gaming ecosystem through its integrated platform, which combines award-winning creative services, data analytics, talent management, and owned media assets to deliver measurable outcomes for brands and publishers.
Establishment Labs (NASDAQ: ESTA - Get Free Report) and Intelligent Bio Solutions (NASDAQ: INBS - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation. Earnings and Valuation This table compares
Shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2026, before the market opens on Wednesday, May 6, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, Dial: 877-407-8037 (US & Cana.
37,500 shares were sold indirectly for a total transaction value of approximately $2.45 million on April 14, 2026. All shares sold were indirectly held via Sariel Group Ltd, with no direct shares sold; after the trade, the insider retains 45,193 direct shares and 1,182,504 indirect shares, per the Form 4.
Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $65.23, for a total value of $2,446,125.00. Following the transaction, the director owned 1,182,504 shares of
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has surpassed more than five million Motiva devices in market. This milestone underscores the company's long‑standing commitment to science‑based innovation and reflects sustained global adoption of Motiva's portfolio of breast aesthetics and reconstruction.
Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 3,575 shares of the stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $60.08, for a total value of $214,786.00. Following the completion of the transaction, the director owned 1,220,004
Establishment Labs (NASDAQ: ESTA - Get Free Report) and HealthEquity (NASDAQ: HQY - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability. Valuation and Earnings This table compares Establishment Labs and
